Product Pipeline

From Bench to Bedside

Our lead product, CAP-1002, is an allogeneic cardiosphere-derived cell (CDC) product that we are currently developing for the treatment of Duchenne muscular dystrophy (DMD). Our exosome product, CAP-2003 is in pre-clinical development for a variety of inflammatory disorders.



Capricor product-pipeline